Exelixis stock rises as key drug Cabometyx withstands patent challenge
Fierce Pharma
OCTOBER 16, 2024
A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively pushing the earliest generic entry out to 2030. | A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively pushing the earliest generic entry out to 2030.
Let's personalize your content